Business Wire
New Data on DARZALEX® ▼ (daratumumab) from the GRIFFIN Study Show Deeper and Extensive Responses in Newly Diagnosed Multiple Myeloma Patients
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data from the randomized phase II GRIFFIN study showing that the addition of DARZALEX® ▼ (daratumumab) to lenalidomide, bortezomib and dexamethasone (D-RVd), followed by the therapy of maintenance with daratumumab plus lenalidomide (DR), resulted in more profound and improved processes, including minimal residual disease (MRD) negativity compared to RVd followed only by R in patients with newly diagnosed multiple myeloma and are eligible for bone marrow transplantation.1 The data obtained investigating the use of daratumumab in combination with RVd (shared in both oral and poster individual presentations at the 2020 Annual Meeting of the American Society of Hematology). ASH), provide further evidence that this regimen could mean greater efficacy compared to standard treatment. ar for patients with newly diagnosed multiple myeloma (NDMM) who are eligible for a transplant. Longer-term follow-up data were shared in this morning’s presentation (Abstract 549), while in the poster presentation (Abstract 3243) additional data from a run-in safety cohort were presented.1,2
